These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26033708)

  • 21. Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial.
    Zhao Y; Lv F; Chen S; Wang Z; Zhang J; Zhang S; Cao J; Wang L; Cao E; Wang B; Hu X
    BMC Cancer; 2018 Oct; 18(1):1019. PubMed ID: 30348118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.
    Hakamies-Blomqvist L; Luoma M; Sjöström J; Pluzanska A; Sjödin M; Mouridsen H; Ostenstad B; Mjaaland I; Ottosson-Lönn S; Bergh J; Malmström P; Blomqvist C
    Eur J Cancer; 2000 Jul; 36(11):1411-7. PubMed ID: 10899655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
    Tate SC; Andre V; Enas N; Ribba B; Gueorguieva I
    Eur J Cancer; 2016 Oct; 66():95-103. PubMed ID: 27544929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
    Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümüş M; Laktionov K; Hermes B; Cicin I; Rodríguez-Cid J; Wilson J; Kato T; Ramlau R; Novello S; Reddy S; Kopp HG; Piperdi B; Li X; Burke T; Paz-Ares L
    J Clin Oncol; 2020 Jan; 38(3):271-280. PubMed ID: 31751163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).
    Svensson H; Einbeigi Z; Johansson H; Hatschek T; Brandberg Y
    Breast Cancer Res Treat; 2010 Oct; 123(3):785-93. PubMed ID: 20680680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.
    Charton E; Bachet JB; Hammel P; Desramé J; Chibaudel B; Cohen R; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Guerin-Meyer V; Taieb J; Volet J; Louvet C; Anota A; Bonnetain F
    Cancer Med; 2019 Sep; 8(11):5079-5088. PubMed ID: 31314957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
    Sledge GW
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):33-5. PubMed ID: 14768403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.
    Smit EF; van Meerbeeck JP; Lianes P; Debruyne C; Legrand C; Schramel F; Smit H; Gaafar R; Biesma B; Manegold C; Neymark N; Giaccone G;
    J Clin Oncol; 2003 Nov; 21(21):3909-17. PubMed ID: 14581415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
    Fountzilas G; Dafni U; Dimopoulos MA; Koutras A; Skarlos D; Papakostas P; Gogas H; Bafaloukos D; Kalogera-Fountzila A; Samantas E; Briasoulis E; Pectasides D; Maniadakis N; Matsiakou F; Aravantinos G; Papadimitriou C; Karina M; Christodoulou C; Kosmidis P; Kalofonos HP
    Breast Cancer Res Treat; 2009 May; 115(1):87-99. PubMed ID: 18483853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.
    Barlesi F; Chouaid C; Crequit J; Le Caer H; Pujol JL; Legodec J; Vergnenegre A; Le Treut J; Fabre-Guillevin E; Loundou A; Auquier P; Simeoni MC; Thomas PA
    Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):783-90. PubMed ID: 25765952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer.
    Picozzi V; Narayanan S; Henry Hu X; Vacirca J
    J Gastrointest Cancer; 2017 Mar; 48(1):103-109. PubMed ID: 28028766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
    Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
    Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
    Demiray M; Kurt E; Evrensel T; Kanat O; Arslan M; Saraydaroglu O; Ercan I; Gonullu G; Gokgoz S; Topal U; Tolunay S; Tasdelen I; Manavoglu O
    Cancer Invest; 2005; 23(5):386-91. PubMed ID: 16193637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
    Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
    BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial.
    Yamaguchi K; Shimada Y; Hironaka S; Sugimoto N; Komatsu Y; Nishina T; Omuro Y; Tamura T; Piao Y; Homma G; Jen MH; Liepa AM; Muro K
    Clin Drug Investig; 2021 Jan; 41(1):53-64. PubMed ID: 33355909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.
    Xu B; Jiang Z; Kim SB; Yu S; Feng J; Malzyner A; Del Giglio A; Chung HC; Shen LJ; Pen DL
    Breast Cancer; 2011 Jul; 18(3):203-12. PubMed ID: 21465229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemcitabine plus paclitaxel in breast cancer.
    Yardley DA
    Semin Oncol; 2005 Aug; 32(4 Suppl 6):S14-21. PubMed ID: 16143163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.
    Quoix E; Audigier-Valette C; Lavolé A; Molinier O; Westeel V; Barlesi F; Le Treut J; Pichon E; Dauba J; Otto J; Moreau L; Madelaine J; Dumont P; Margery J; Debieuvre D; Renault PA; Pujol JL; Langlais A; Morin F; Moro-Sibilot D; Souquet PJ
    Eur J Cancer; 2020 Oct; 138():193-201. PubMed ID: 32898792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer.
    Murad AM; Guimarães RC; Aragão BC; Scalabrini-Neto AO; Rodrigues VH; Garcia R
    Am J Clin Oncol; 2001 Jun; 24(3):264-8. PubMed ID: 11404498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.